5/17
01:55 pm
ubx
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy [Yahoo! Finance]
Low
Report
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy [Yahoo! Finance]
5/15
09:09 pm
ubx
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress [Yahoo! Finance]
Medium
Report
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress [Yahoo! Finance]
5/15
12:25 pm
ubx
Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
5/14
05:14 pm
ubx
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
5/14
05:00 pm
ubx
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
Low
Report
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
4/25
08:00 am
ubx
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
Low
Report
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
4/24
09:10 pm
ubx
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST [Yahoo! Finance]
Low
Report
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST [Yahoo! Finance]
4/23
08:00 am
ubx
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
Low
Report
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
4/16
08:00 am
ubx
Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
4/15
07:10 am
ubx
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
4/15
07:00 am
ubx
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Low
Report
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4/7
08:03 pm
ubx
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting [Yahoo! Finance]
Medium
Report
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting [Yahoo! Finance]